(VEEV) Veeva Systems - Overview

Sector: Healthcare | Industry: Health Information Services | Exchange: NYSE (USA) | Market Cap: 28.875m USD | Total Return: -23.2% in 12m

Stock Software, Data, Analytics, Consulting
Total Rating 57
Safety 97
Buy Signal -0.44
Health Information Services +7.4
Health Care Technology -2.2
Market Cap: 28,875m
Avg Trading Vol: 310M USD
ATR: 4.05%
Peers RS (IBD): 71.9
Risk 5d forecast
Volatility33.3%
Rel. Tail Risk-12.5%
Reward TTM
Sharpe Ratio-0.69
Alpha-39.08
Character TTM
Beta0.696
Beta Downside0.287
Drawdowns 3y
Max DD43.83%
CAGR/Max DD-0.02
EPS (Earnings per Share) EPS (Earnings per Share) of VEEV over the last years for every Quarter: "2021-04": 0.91, "2021-07": 0.94, "2021-10": 0.97, "2022-01": 0.9, "2022-04": 0.99, "2022-07": 1.03, "2022-10": 1.13, "2023-01": 1.15, "2023-04": 0.91, "2023-07": 1.21, "2023-10": 1.34, "2024-01": 1.38, "2024-04": 1.5, "2024-07": 1.62, "2024-10": 1.13, "2025-01": 1.74, "2025-04": 1.97, "2025-07": 1.99, "2025-10": 2.04, "2026-01": 2.06,
EPS CAGR: 21.58%
EPS Trend: 90.2%
Last SUE: 2.20
Qual. Beats: 14
Revenue Revenue of VEEV over the last years for every Quarter: 2021-04: 433.573, 2021-07: 455.594, 2021-10: 476.111, 2022-01: 485.499, 2022-04: 505.102, 2022-07: 534.218, 2022-10: 552.351, 2023-01: 563.389, 2023-04: 526.325, 2023-07: 590.225, 2023-10: 616.505, 2024-01: 630.618, 2024-04: 650.345, 2024-07: 676.181, 2024-10: 699.207, 2025-01: 720.886, 2025-04: 759.043, 2025-07: 789.081, 2025-10: 811.236, 2026-01: 835.951,
Rev. CAGR: 14.38%
Rev. Trend: 98.7%
Last SUE: 3.01
Qual. Beats: 9
Risks
Technicals: choppy
Description: VEEV Veeva Systems

Veeva Systems Inc. (VEEV) provides cloud-based software and services to the global life sciences industry. Its offerings span commercial, data, and development solutions. The companys business model focuses on recurring revenue from software subscriptions.

Veeva Commercial Cloud includes CRM, medical content management, promotional materials management, and analytics for pharmaceutical and biotechnology companies. Veeva Data Cloud offers customer reference data, deep industry data, and de-identified patient data. Veeva Development Cloud provides solutions for clinical trial execution, data management, safety, and regulatory information management. The company also offers Veeva Quality Cloud for life sciences and consumer products sectors, and business consulting services.

Veeva also provides professional services, including implementation, project management, solution design, and ongoing managed services. The life sciences industry has a high demand for specialized software due to complex regulatory requirements and extensive R&D processes.

For more detailed analysis, consider exploring ValueRays comprehensive reports.

Headlines to Watch Out For
  • Life sciences industry cloud software demand drives subscription revenue growth
  • New product development expands market share in R&D and quality
  • Regulatory changes in life sciences impact software compliance needs
  • Competition from large enterprise software vendors pressures pricing
Piotroski VR‑10 (Strict) 5.5
Net Income: 908.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.15 > 0.02 and ΔFCF/TA 0.90 > 1.0
NWC/Revenue: 199.1% < 20% (prev 178.8%; Δ 20.28% < -1%)
CFO/TA 0.16 > 3% & CFO 1.42b > Net Income 908.9m
Net Debt (-1.33b) to EBITDA (956.3m): -1.39 < 3
Current Ratio: 4.89 > 1.5 & < 3
Outstanding Shares: last quarter (168.3m) vs 12m ago 1.56% < -2%
Gross Margin: 75.53% > 18% (prev 0.75%; Δ 7.48k% > 0.5%)
Asset Turnover: 39.16% > 50% (prev 37.42%; Δ 1.74% > 0%)
Interest Coverage Ratio: -1.28 > 6 (EBITDA TTM 956.3m / Interest Expense TTM -524.0m)
Altman Z'' 9.38
A: 0.71 (Total Current Assets 8.00b - Total Current Liabilities 1.64b) / Total Assets 8.98b
B: 0.49 (Retained Earnings 4.36b / Total Assets 8.98b)
C: 0.08 (EBIT TTM 670.5m / Avg Total Assets 8.16b)
D: 2.48 (Book Value of Equity 4.37b / Total Liabilities 1.76b)
Altman-Z'' Score: 9.38 = AAA
Beneish M -3.07
DSRI: 1.07 (Receivables 1.31b/1.06b, Revenue 3.20b/2.75b)
GMI: 0.99 (GM 75.53% / 74.53%)
AQI: 0.75 (AQ_t 0.09 / AQ_t-1 0.12)
SGI: 1.16 (Revenue 3.20b / 2.75b)
TATA: -0.06 (NI 908.9m - CFO 1.42b) / TA 8.98b)
Beneish M-Score: -3.07 (Cap -4..+1) = AA
What is the price of VEEV shares? As of April 03, 2026, the stock is trading at USD 175.66 with a total of 1,845,888 shares traded.
Over the past week, the price has changed by -2.41%, over one month by -4.12%, over three months by -20.73% and over the past year by -23.20%.
Is VEEV a buy, sell or hold? Veeva Systems has received a consensus analysts rating of 3.88. Therefore, it is recommended to buy VEEV.
  • StrongBuy: 12
  • Buy: 7
  • Hold: 11
  • Sell: 1
  • StrongSell: 1
What are the forecasts/targets for the VEEV price?
Wallstreet Target Price 270.9 54.2%
Analysts Target Price 270.9 54.2%
VEEV Fundamental Data Overview as of 02 April 2026
P/E Trailing = 32.2312
P/E Forward = 35.3357
P/S = 9.0368
P/B = 7.4266
P/EG = 1.3872
Revenue TTM = 3.20b USD
EBIT TTM = 670.5m USD
EBITDA TTM = 956.3m USD
Long Term Debt = 95.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 12.2m USD (from shortTermDebt, last quarter)
Debt = 95.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -1.33b USD (from netDebt column, last quarter)
Enterprise Value = 22.41b USD (28.88b + Debt 95.9m - CCE 6.56b)
Interest Coverage Ratio = -1.28 (Ebit TTM 670.5m / Interest Expense TTM -524.0m)
EV/FCF = 16.13x (Enterprise Value 22.41b / FCF TTM 1.39b)
FCF Yield = 6.20% (FCF TTM 1.39b / Enterprise Value 22.41b)
FCF Margin = 43.49% (FCF TTM 1.39b / Revenue TTM 3.20b)
Net Margin = 28.44% (Net Income TTM 908.9m / Revenue TTM 3.20b)
Gross Margin = 75.53% ((Revenue TTM 3.20b - Cost of Revenue TTM 782.0m) / Revenue TTM)
Gross Margin QoQ = 74.46% (prev 75.41%)
Tobins Q-Ratio = 2.50 (Enterprise Value 22.41b / Total Assets 8.98b)
Interest Expense / Debt = 31.55% (Interest Expense 30.2m / Debt 95.9m)
Taxrate = 23.09% (73.3m / 317.5m)
NOPAT = 515.6m (EBIT 670.5m * (1 - 23.09%))
Current Ratio = 4.89 (Total Current Assets 8.00b / Total Current Liabilities 1.64b)
Debt / Equity = 0.01 (Debt 95.9m / totalStockholderEquity, last quarter 7.21b)
Debt / EBITDA = -1.39 (Net Debt -1.33b / EBITDA 956.3m)
Debt / FCF = -0.95 (Net Debt -1.33b / FCF TTM 1.39b)
Total Stockholder Equity = 6.78b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.14% (Net Income 908.9m / Total Assets 8.98b)
RoE = 13.41% (Net Income TTM 908.9m / Total Stockholder Equity 6.78b)
RoCE = 9.76% (EBIT 670.5m / Capital Employed (Equity 6.78b + L.T.Debt 95.9m))
RoIC = 7.61% (NOPAT 515.6m / Invested Capital 6.78b)
WACC = 8.48% (E(28.88b)/V(28.97b) * Re(8.43%) + D(95.9m)/V(28.97b) * Rd(31.55%) * (1-Tc(0.23)))
Discount Rate = 8.43% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.99%
[DCF] Terminal Value 79.42% ; FCFF base≈1.26b ; Y1≈1.49b ; Y5≈2.31b
[DCF] Fair Price = 230.7 (EV 36.36b - Net Debt -1.33b = Equity 37.68b / Shares 163.3m; r=8.48% [WACC]; 5y FCF grow 19.46% → 3.0% )
EPS Correlation: 90.18 | EPS CAGR: 21.58% | SUE: 2.20 | # QB: 14
Revenue Correlation: 98.71 | Revenue CAGR: 14.38% | SUE: 3.01 | # QB: 9
EPS next Quarter (2026-07-31): EPS=2.19 | Chg7d=+0.001 | Chg30d=+0.053 | Revisions Net=+12 | Analysts=26
EPS current Year (2027-01-31): EPS=8.83 | Chg7d=+0.004 | Chg30d=+0.239 | Revisions Net=+26 | Growth EPS=+9.1% | Growth Revenue=+12.7%
EPS next Year (2028-01-31): EPS=9.89 | Chg7d=-0.001 | Chg30d=+0.069 | Revisions Net=+13 | Growth EPS=+11.9% | Growth Revenue=+12.2%
[Analyst] Revisions Ratio: +0.75 (14 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 5.3% (Discount Rate 8.4% - Earnings Yield 3.1%)
[Growth] Growth Spread = +7.2% (Analyst 12.5% - Implied 5.3%)
External Resources
Dataroma Stockcircle